Adjudin is primarily investigated for its potential application as a male contraceptive. It works by disrupting the integrity of the Sertoli-germ cell junctions in the testes, leading to the detachment of developing sperm cells and resulting in temporary infertility. This mechanism offers a reversible approach to male contraception, making it a promising candidate for non-hormonal birth control methods. Additionally, Adjudin has been studied for its potential anti-cancer properties, particularly in targeting cancer cell adhesion and migration, which could be beneficial in inhibiting tumor progression. Research is ongoing to explore its efficacy and safety in these applications.